ALIVUSNSEAlivus Life Sciences LimitedLowNeutral
Announced Sat, 21 Mar · 12:52 IST

Alivus Life Sciences Limited has informed the Exchange about General Updates

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹952.85
prior close
₹939.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2-1.0-0.9-1.1+1.5+3.4+3.6+2.4+4.7+6.5+11.6+11.3+11.5+17.2
Up moveDown movePending
AI summary

Alivus Life Sciences has received an assessment order from the Income Tax Department's Faceless Assessment Unit dated 20th March 2026, under Section 143(1) read with Section 144B of the Income Tax Act, 1961. The order pertains to Assessment Year 2023-24 (Financial Year 2022-23) and raises a tax demand of Rs. 2,60,67,810 (about Rs. 2.61 crore) including applicable interest. The demand arises from disallowances of expenditure under Section 37(1) of the Income Tax Act. The company has stated there is no material impact on its financials, operations, or other activities, and is evaluating its right to appeal before the appellate authority.

Likely market impact

The Rs. 2.61 crore tax demand is modest for a listed company and the management has downplayed any material financial impact, but if the disallowance stands it would be an additional outgo. Investors should watch for the company's decision on appeal, as an adverse ruling could set a precedent for future assessments.